<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Acta Neuropathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Acta Neuropathol</journal-id>
      <journal-title-group>
        <journal-title>Acta Neuropathologica</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0001-6322</issn>
      <issn pub-type="epub">1432-0533</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23404372</article-id>
      <article-id pub-id-type="pmc">3681325</article-id>
      <article-id pub-id-type="publisher-id">1096</article-id>
      <article-id pub-id-type="doi">10.1007/s00401-013-1096-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>&#x3B1;-Synucleinopathy associated with G51D <italic>SNCA</italic> mutation: a link between Parkinson&#x2019;s disease and multiple system atrophy?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kiely</surname>
            <given-names>Aoife P.</given-names>
          </name>
          <address>
            <email>a.kiely@ucl.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Asi</surname>
            <given-names>Yasmine T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kara</surname>
            <given-names>Eleanna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Limousin</surname>
            <given-names>Patricia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ling</surname>
            <given-names>Helen</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lewis</surname>
            <given-names>Patrick</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
          <xref ref-type="aff" rid="Aff7"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Proukakis</surname>
            <given-names>Christos</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quinn</surname>
            <given-names>Niall</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lees</surname>
            <given-names>Andrew J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Revesz</surname>
            <given-names>Tamas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houlden</surname>
            <given-names>Henry</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holton</surname>
            <given-names>Janice L.</given-names>
          </name>
          <address>
            <email>janice.holton@ucl.ac.uk</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Queen Square Brain Bank, UCL Institute of Neurology, London, UK </aff>
        <aff id="Aff2"><label/>Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK </aff>
        <aff id="Aff3"><label/>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK </aff>
        <aff id="Aff4"><label/>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK </aff>
        <aff id="Aff5"><label/>Unit of Functional Neurosurgery, UCL Institute of Neurology, London, UK </aff>
        <aff id="Aff6"><label/>Sobell Department of Motor Neuroscience and Movement Disorders, University College London, London, UK </aff>
        <aff id="Aff7"><label/>School of Pharmacy, University of Reading, Whiteknights, Reading, UK </aff>
        <aff id="Aff8"><label/>Department of Clinical Neuroscience, UCL Institute of Neurology, London, UK </aff>
        <aff id="Aff9"><label/>National Hospital for Neurology and Neurosurgery, Queen Square, London, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>2</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>2</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2013</year>
      </pub-date>
      <volume>125</volume>
      <issue>5</issue>
      <fpage>753</fpage>
      <lpage>769</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>2</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>We report a British family with young-onset Parkinson&#x2019;s disease (PD) and a G51D <italic>SNCA</italic> mutation that segregates with the disease. Family history was consistent with autosomal dominant inheritance as both the father and sister of the proband developed levodopa-responsive parkinsonism with onset in their late thirties. Clinical features show similarity to those seen in families with <italic>SNCA</italic> triplication and to cases of A53T <italic>SNCA</italic> mutation. Post-mortem brain examination of the proband revealed atrophy affecting frontal and temporal lobes in addition to the caudate, putamen, globus pallidus and amygdala. There was severe loss of pigmentation in the substantia nigra and pallor of the locus coeruleus. Neuronal loss was most marked in frontal and temporal cortices, hippocampal CA2/3 subregions, substantia nigra, locus coeruleus and dorsal motor nucleus of the vagus. The cellular pathology included widespread and frequent neuronal &#x3B1;-synuclein immunoreactive inclusions of variable morphology and oligodendroglial inclusions similar to the glial cytoplasmic inclusions of multiple system atrophy (MSA). Both inclusion types were ubiquitin and p62 positive and were labelled with phosphorylation-dependent anti-&#x3B1;-synuclein antibodies In addition, TDP-43 immunoreactive inclusions were observed in limbic regions and in the striatum. Together the data show clinical and neuropathological similarities to both the A53T <italic>SNCA</italic> mutation and multiplication cases. The cellular neuropathological features of this case share some characteristics of both PD and MSA with additional unique striatal and neocortical pathology. Greater understanding of the disease mechanism underlying the G51D mutation could aid in understanding of &#x3B1;-synuclein biology and its impact on disease phenotype.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s00401-013-1096-7) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Parkinson&#x2019;s disease</kwd>
        <kwd>Multiple system atrophy</kwd>
        <kwd>&#x3B1;-Synuclein</kwd>
        <kwd>SNCA</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2013</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>The term &#x3B1;-synucleinopathy unites a group of neurodegenerative diseases which share the pathological hallmark of fibrillary inclusions in which &#x3B1;-synuclein protein is the major component. The three most common members of this group are Parkinson&#x2019;s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). PD and DLB have common neuropathological features including deposition of fibrillar &#x3B1;-synuclein in Lewy bodies (LB) and Lewy neurites (LN). In MSA, &#x3B1;-synuclein is aggregated in oligodendrocytes forming the hallmark lesion, the glial cytoplasmic inclusion (GCI), and also in neuronal cytoplasmic inclusions (NCIs), cell processes and to a lesser extent in neuronal and glial nuclei [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
      <p>Several missense mutations of the <italic>SNCA</italic> gene have been identified in families with autosomal dominant forms of PD. No <italic>SNCA</italic> mutation has been linked with MSA, however, polymorphisms of the gene have been associated with increased risk of the disease in Caucasian populations, although these results have not been replicated in all populations [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. The <italic>SNCA</italic> gene, which encodes the 140-amino acid protein &#x3B1;-synuclein, is located on chromosome 4q21-23. In Parkinson&#x2019;s disease, the first <italic>SNCA</italic> mutation to be described was A53T in a Greek-Italian family [<xref ref-type="bibr" rid="CR62">62</xref>] and this was subsequently identified in families of Asian, Swedish and Polish origin [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Two further missense mutations of <italic>SNCA</italic> were identified, A30P [<xref ref-type="bibr" rid="CR43">43</xref>] and E46K [<xref ref-type="bibr" rid="CR84">84</xref>] in German and Basque families, respectively. Very recently, we have reported the novel H50Q <italic>SNCA</italic> mutation [<xref ref-type="bibr" rid="CR65">65</xref>]. Missense mutations in the N-terminal region of &#x3B1;-synuclein are reported to have a direct impact on &#x3B1;-synuclein conformation and function. The A53T and E46K mutant forms of &#x3B1;-synuclein exhibit faster fibrillisation kinetics than wild-type protein [<xref ref-type="bibr" rid="CR12">12</xref>], while fibrillisation of the A30P mutant protein is slower and results in fewer complex fibrils in LBs [<xref ref-type="bibr" rid="CR47">47</xref>]. Duplication and triplication of <italic>SNCA</italic> have been discovered in a small number of families and sporadic cases of levodopa-responsive PD and, where described, pathological features of PD, in addition to GCIs similar to those of MSA, are observed [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. The number of <italic>SNCA</italic> locus replicates is known to influence disease progression, such that triplication causes earlier onset and a more rapid clinical course than <italic>SNCA</italic> duplication [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR75">75</xref>].</p>
      <p>Pathological inclusions of fibrillar &#x3B1;-synuclein have distinct morphologies and distribution depending on disease type. For example, in PD, the characteristic LBs and LNs occur in brainstem nuclei and usually exhibit a hierarchical spread to involve limbic and neocortical regions with disease progression [<xref ref-type="bibr" rid="CR8">8</xref>], although not all cases conform to the proposed pattern of disease progression [<xref ref-type="bibr" rid="CR36">36</xref>]. In MSA, GCIs are the most abundant form of fibrillar &#x3B1;-synuclein inclusion and together with neuronal cytoplasmic or nuclear inclusions are distributed widely in the striatonigral, olivopontocerebellar and other regions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR60">60</xref>].</p>
      <p>We report a family with young-onset PD and a mutation in <italic>SNCA</italic> that segregates with the disease. We describe an &#x3B1;-synucleinopathy with both PD and MSA-like neuropathological features together with involvement of the striatum and severe CA2/3 neuronal loss. The distribution of neuronal and oligodendroglial inclusions immunoreactive for &#x3B1;-synuclein, ubiquitin and p62 is described. The phosphorylation state of &#x3B1;-synuclein within inclusions and the relationship of &#x3B1;-synuclein to intracellular accumulation of tau and TDP-43 are also investigated. Together the evidence reveals neuropathological similarities to both the A53T <italic>SNCA</italic> mutation and multiplication cases with additional unique striatal and neocortical pathology [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Brain tissue</title>
        <p>The brain was donated to the Queen Square Brain Bank for Neurological Disorders, UCL Institute of Neurology using ethically approved protocols and stored for research under a licence issued by the Human Tissue Authority (No. 12198). Following fixation in 10&#xA0;% buffered formalin, the right half brain was sliced in the coronal plane, examined and blocks were selected for paraffin wax embedding and histology.</p>
        <p>Paraffin-embedded sections (8&#xA0;&#x3BC;m) were stained using haematoxylin and eosin (H&amp;E), Luxol fast blue/cresyl violet and Gallyas silver impregnation. Immunohistochemistry was performed as previously described [<xref ref-type="bibr" rid="CR58">58</xref>] using primary antibodies detailed in Online Resource 1. Double immunofluorescence was detected using isotype specific anti-rabbit IgG or anti-mouse IgG secondary antibodies conjugated with either Alexa 488 or 594 fluorescent dyes (1:400) (Life technologies, Paisley, UK) followed by quenching of autofluorescence with 0.1&#xA0;% Sudan Black/70&#xA0;% ethanol (Sigma-Aldrich, Dorset, UK) solution for 10&#xA0;min and mounting with glass coverslips using VECTAshield mounting media with 4&#x2032;,6-diamidino-2-phenylindole (DAPI) nuclear stain (Vector laboratories, Peterborough, UK). Images were visualised using confocal fluorescence microscopy (Leica DM5500 B).</p>
      </sec>
      <sec id="Sec4">
        <title>Genetics</title>
        <p>Sanger sequencing was performed for exon 3 of <italic>SNCA</italic> on family members for whom a DNA sample was available (affected sibling and unaffected mother). Genomic DNA was amplified through polymerase chain reaction (PCR) with the Roche Fast start master mix kit (primer sequences available upon request). After purification, the PCR product was sequenced bi-directionally with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied biosystems). Purified sequencing reaction products were run on ABI 3730xl DNA analyser, sequencing results were analysed on Sequencher version 4.1.4 and variants identified were named based on the GenBank reference sequence with accession numbers NM_001146055.1 and NP_001139527.1. Variants identified were verified through re-sequencing a duplicate genomic DNA sample. To exclude larger genomic rearrangements in the <italic>SNCA</italic> region, genomic DNA samples from both affected siblings were run on Illumina Human660W-Quad BeadChip arrays and the results were analysed on Illumina Genome studio V2010.2.</p>
      </sec>
      <sec id="Sec5">
        <title>Sequence alignment</title>
        <p>Amino acid sequence data for &#x3B1;-synuclein from <italic>Homo</italic><italic>sapiens</italic>, <italic>Pan troglodytes</italic>, <italic>Sus scrofa</italic>, <italic>Mus musculus</italic>, <italic>Bos taurus</italic>, <italic>Xenopus laevis</italic> and <italic>Gallus gallus</italic>, along with amino acid sequence data for human &#x3B2; and &#x3B3; synuclein, were downloaded from NCBI. Sequence alignment was carried out using the basic local alignment search tool (BLAST, <ext-link ext-link-type="uri" xlink:href="http://blast.ncbi.nlm.nih.gov">http://blast.ncbi.nlm.nih.gov</ext-link>). Secondary structure data for &#x3B1;-synuclein are based upon data from Ulmer and coworkers [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="results">
      <title>Results</title>
      <sec id="Sec7">
        <title>Case history</title>
        <p>At age 19, this British man presented with stiffness and tremor in his left hand. Examination revealed a classical parkinsonian rest tremor of the left arm and leg with bradykinesia, cogwheel rigidity and reduced left arm swing on walking. Eye movements were normal. His symptoms gradually involved his right side and he had a parkinsonian gait. At age 25, levodopa therapy was started with a good initial response, but 7&#xA0;months later, he developed levodopa-induced choreiform movements which continued to be troublesome for a decade. Since age 28, he had progressive cognitive impairment with a mini mental state examination (MMSE) score of 24/30 at age 30 and 19/30 at age 32, neuropsychometry showed visual and verbal memory impairments and he later developed visual hallucination. At age 33, he was incapacitated by severe dysarthria, severe akinetic rigidity, postural hypotension with syncope and postural instability. Examination revealed limb myoclonus, spasticity and bilateral extensor plantar response. He started to have seizures in the last 8&#xA0;years of his life but these were controlled using sodium valproate. He died at age 49 with a disease duration of 29&#xA0;years.</p>
        <p>His father died of a similar illness with onset of motor symptoms at age 39 and later developed dementia and died of sepsis at age 47. His sister developed parkinsonism at age 40 and has had a good persistent levodopa response. She is now 48&#xA0;years old and has mild peak dose dyskinesia, occasional visual hallucination and has not noted any cognitive impairment. The case history of the proband was previously published in a series on young onset Parkinson&#x2019;s disease (case 2M) [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Genetics</title>
        <p>In the affected family members, an &#x3B1;-synuclein G&#xA0;&gt;&#xA0;A heterozygous mutation at base 152, codon 51 causing a glycine to aspartic acid amino acid change (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). This mutation segregated with the disease in the family (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b) and was not seen in over 4,500 control individuals. Multiplication of the &#x3B1;-synuclein gene had been previously excluded by SNP array analysis. The mutated amino acid is highly conserved across species down to invertebrates and is predicted to be damaging using PolyPhen-2 and SIFT (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p><italic>SNCA</italic> mutation G51D. Chromatogram (<italic>red</italic> thymine, <italic>blue</italic> cytosine, <italic>green</italic> adenine and <italic>black</italic> guanine). Sanger sequencing of the SNCA gene identified a c.G152A mutation (<italic>upper arrows</italic>) in exon 3 of this gene as shown. This created a glycine to aspartic acid amino acid change (<italic>lower arrows</italic>)</p></caption><graphic xlink:href="401_2013_1096_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>&#x3B1;-Synuclein protein structure and conservation as shown by amino acid sequence alignment. Amino acid sequence of human &#x3B1;-synuclein, showing regions of secondary structure (alpha helices highlighted in <italic>green</italic>). The G51 residue is indicated by an <italic>arrow</italic>, and sits in the middle of helix 2 <bold>(a</bold>). Sequence alignment of &#x3B1;-synuclein amino acid sequences from <italic>Homo sapiens</italic>, <italic>Pan troglodytes</italic>, <italic>Sus scrofa</italic>, <italic>Mus musculus</italic>, <italic>Bos taurus</italic>, <italic>Xenopus laevis</italic> and <italic>Gallus gallus</italic>. The G51 residue highlighted in <italic>yellow</italic> and indicated by an <italic>arrow</italic> is conserved throughout these organisms (<bold>b</bold>). Sequence alignment of human &#x3B1;-, &#x3B2;- and &#x3B3;-synuclein amino acid sequences, with the G51 residue is highlighted in <italic>yellow</italic> and indicated by an <italic>arrow</italic> (<bold>c</bold>). This residue is conserved in &#x3B1;- and &#x3B2;-synuclein, but is replaced by a serine residue in &#x3B3;-synuclein</p></caption><graphic xlink:href="401_2013_1096_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Neuropathological findings</title>
        <p>The brain weighed 1,036&#xA0;g and showed frontal and anterior temporal lobe atrophy (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). The hippocampus, amygdala, caudate, putamen and globus pallidus were reduced in volume and showed greyish discolouration (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). The subthalamic nucleus was of normal size with mild brown discolouration (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b). There was severe loss of pigmentation of the substantia nigra (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c, arrow) and mild pallor of the locus coeruleus (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>d, arrow). The medulla and cerebellum were macroscopically unremarkable (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>e).<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Macroscopic features. Macroscopic images of formalin fixed right hemispheric brain slices (<bold>a</bold>, <bold>b</bold>), midbrain (<bold>c</bold>), pons (<bold>d</bold>) and cerebellum (<bold>e</bold>). There was severe atrophy of the temporal cortex with relative preservation of the superior temporal gyrus (<bold>a</bold>, <bold>b</bold>) and severe reduction in volume of white matter with thinning of the corpus callosum (<bold>a</bold>, <bold>b</bold><italic>white asterisks</italic>). The caudate nucleus was reduced in volume (<bold>a</bold>, <bold>b</bold><italic>arrow heads</italic>). There was reduction in size and grey discolouration of both the putamen and the globus pallidus (<bold>a</bold>, <bold>b</bold>). The amygdala was small and darkly coloured (<bold>a</bold>, <italic>black asterisk</italic>). The hippocampus was moderately reduced in volume (<bold>b</bold>). The midbrain showed marked depigmentation of the substantia nigra (<bold>c</bold>, <italic>arrow</italic>). The pons was well preserved with severe pallor of the locus coeruleus (<bold>d</bold>, <italic>arrow</italic>). The cerebellum was macroscopically normal and the white matter was well preserved (<bold>e</bold>). <italic>Scale bars</italic> represent 15&#xA0;mm</p></caption><graphic xlink:href="401_2013_1096_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Histological findings</title>
        <p>Histological findings are summarised in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> and illustrated in Figs.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref> and <xref rid="Fig5" ref-type="fig">5</xref>. The neocortical regions showed marked superficial vacuolation with neuronal loss and gliosis in all regions except the occipital cortex. Cortical neuronal depletion was most severe in the anterior temporal, piriform and insular cortices. In the hippocampal formation, neuronal loss affected all regions except the dentate fascia (DF) and this was most striking and severe in the CA2 and CA3 subregions where there was almost complete neuronal loss with accompanying gliosis. Mild neuronal loss accompanied by severe and uniformly distributed gliosis was observed in the caudate and putamen (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>i, j). There were virtually no remaining pigmented neurons in the substantia nigra pars compacta (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>h), and there was severe loss of neurons in the locus coeruleus and the dorsal motor nucleus of the vagus (DMV). No classical intraneuronal LBs were seen in the substantia nigra, locus coeruleus or DMV in H&amp;E stained sections, likely due to the very severe neuronal loss. Cerebellar Purkinje cells were moderately depleted while the dentate nucleus was well preserved. In the rostral cervical spinal cord, the anterior horn motor neurons were preserved. Weakly basophilic NCIs with varied morphology, including well-defined round or oval structures and perinuclear annular or crescent shapes, were widespread and were prominent in the hippocampus, neocortex and striatum (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a&#x2013;k). Balloon neurons, best identified by &#x3B1;B-crystallin immunohistochemistry, were present in the frontal and temporal cortices and were most numerous in the cingulate gyrus (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>g).<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Semi-quantitative assessment and regional distribution of neuronal loss and &#x3B1;-synuclein pathology</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Neuronal loss</th><th align="left" colspan="4">Neuronal &#x3B1;-synuclein pathology</th><th align="left" rowspan="2">&#x3B1;-Synuclein threads</th><th align="left" rowspan="2">Oligodendroglial &#x3B1;-synuclein inclusions</th></tr><tr><th align="left">Annular or crescent</th><th align="left">Globular</th><th align="left">Diffuse</th><th align="left">NFT-like</th></tr></thead><tbody><tr><td align="left" colspan="8">Cortex</td></tr><tr><td align="left">&#xA0;Frontal</td><td align="left">+</td><td align="left">++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Motor</td><td align="left">+</td><td align="left">++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Temporal</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Parietal</td><td align="left">+</td><td align="left">+++</td><td align="left">++</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Occipital</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Cingulate</td><td align="left">++</td><td align="left">+++</td><td align="left">++</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Insular</td><td align="left">+++</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left" colspan="8">Sub-cortical white matter</td></tr><tr><td align="left">&#xA0;Frontal</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Motor</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">++</td></tr><tr><td align="left">&#xA0;Temporal</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Parietal</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Occipital</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Cingulate</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Internal capsule</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;External capsule</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Amygdala</td><td align="left">+++</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">+</td></tr><tr><td align="left" colspan="8">Hippocampus</td></tr><tr><td align="left">&#xA0;DF</td><td align="left">&#x2013;</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;CA4</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;CA3</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;CA2</td><td align="left">+++</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;CA1</td><td align="left">+</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Subiculum</td><td align="left">+</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">+</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Entorhinal cortex</td><td align="left">++</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Transentorhinal cortex</td><td align="left">++</td><td align="left">++</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Caudate</td><td align="left">+</td><td align="left">+</td><td align="left">+++</td><td align="left">++</td><td align="left">+</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Putamen</td><td align="left">+</td><td align="left">++</td><td align="left">+++</td><td align="left">++</td><td align="left">+</td><td align="left">+++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Globus pallidus</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Thalamus</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Subthalamic nucleus</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Red nucleus</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">&#xA0;III nerve nucleus</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Substantia nigra</td><td align="left">+++</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">+</td></tr><tr><td align="left">&#xA0;Locus coeruleus</td><td align="left">+++</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Pontine nuclei</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">Pontine base white matter</td><td align="left">N/A</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">++</td></tr><tr><td align="left">&#xA0;Dorsal motor nucleus of vagus</td><td align="left">+++</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Twelfth nerve nucleus</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Inferior olive</td><td align="left">+</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">++</td><td align="left">&#x2013;</td><td align="left">+</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Cerebellar hemisphere Purkinje cells</td><td align="left">++</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">N/A</td></tr><tr><td align="left">&#xA0;Cerebellar hemisphere white matter</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">++</td><td align="left">++</td></tr><tr><td align="left">&#xA0;Dentate nucleus</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Cervical cord anterior horn</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">&#xA0;Cervical cord white matter</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">+</td><td align="left">&#x2013;</td></tr></tbody></table><table-wrap-foot><p>Oligodendroglial &#x3B1;-synuclein: cytoplasmic inclusions usually with similar morphology to GCIs of MSA, less frequently resembling coiled bodies</p><p><italic>N/A</italic> not applicable, <italic>NFT</italic> neurofibrillary tangle</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Histological findings. Representative images from the hippocampus (<bold>a</bold>&#x2013;<bold>e</bold>), insular cortex (<italic>ins</italic>, <bold>f</bold>), cingulate gyrus (<italic>Cg</italic>, <bold>g</bold>), substantia nigra (<italic>SN</italic>, <bold>h</bold>) and putamen (<italic>put</italic>, <bold>i</bold>&#x2013;<bold>k</bold>). In the hippocampus, there was severe neuronal loss in the CA2 and CA3 (<bold>a</bold>, <italic>arrows</italic>). The CA2 showed few residual neurons (<bold>b</bold>). Neuronal inclusions (<italic>arrows</italic>) with varying morphology are illustrated in the CA1 (<bold>c</bold>), CA3 (<bold>d</bold>) and the dentate fascia (<italic>DF</italic>, <bold>e</bold>). Superficial laminae of the neocortex showed marked neuronal loss with microvacuolation illustrated in the insular cortex (<italic>ins</italic>, <bold>f</bold>). Ballooned neurons were most frequent in the cingulate gyrus (<italic>Cg</italic>, <bold>g</bold>). The substantia nigra (<italic>SN</italic>) shows severe loss of pigmented neurons accompanied by gliosis (<bold>h</bold>). Abundant eosinophilic reactive astrocytes are visualised in the putamen (<italic>put</italic>, <bold>i</bold>) and confirmed by GFAP immunohistochemistry (<bold>j</bold>). TDP-43 immunoreactive inclusions were also detected in the putamen (<bold>k</bold>). Luxol fast blue (<bold>a</bold>), haematoxylin and eosin (<italic>H&amp;E</italic>) (<bold>b</bold>&#x2013;<bold>f</bold>, <bold>h</bold>, <bold>i</bold>), &#x3B1;B-crystallin (<bold>g</bold>), GFAP (<bold>j</bold>) TDP-43 (<bold>k</bold>). <italic>Scale bar</italic> 150&#xA0;&#x3BC;m (<bold>a</bold>), scale bars in <bold>b</bold>, <bold>e</bold>&#x2013;<bold>h</bold>, <bold>k</bold> represent 50&#xA0;&#x3BC;m (<bold>c</bold>&#x2013;<bold>e</bold> are at the same magnification, as are <bold>i</bold>&#x2013;<bold>k</bold>)</p></caption><graphic xlink:href="401_2013_1096_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Characterisation of neuronal and glial &#x3B1;-synuclein inclusions. Thread-like &#x3B1;-synuclein immunoreactivity was observed to be widespread, shown here within the hippocampal regions CA1, CA3 and CA4 (<bold>a</bold>&#x2013;<bold>c</bold>), caudate nucleus (<italic>Cd</italic>, <bold>e</bold>), putamen (<italic>put</italic>, <bold>f</bold>) and insular cortex (<italic>ins</italic>, <bold>g</bold>, <bold>h</bold>). Neuronal cytoplasmic inclusions immunoreactive for &#x3B1;-synuclein had a number of different morphological appearances globular (<bold>i</bold>), annular (<bold>j</bold>), neurofibrillary tangle-like (<bold>k</bold>) and diffuse (<bold>l</bold>). Gallyas silver impregnation demonstrated the presence of fibrillar protein in neuronal inclusions (<italic>DF</italic>, <italic>m</italic> and <italic>CA4</italic>, <bold>n</bold>) and also in GCI-like inclusions (pontine base, <bold>o</bold>). <italic>Scale bars</italic> in <bold>e</bold>&#x2013;<bold>h</bold>, <bold>l</bold> represent 50&#xA0;&#x3BC;m (<bold>a</bold>&#x2013;<bold>n</bold>) (<bold>a</bold>&#x2013;<bold>e</bold> are at the same magnification as are <bold>i</bold>&#x2013;<bold>l</bold>, <bold>m</bold> and <bold>n</bold>). <italic>Scale bar</italic> in <bold>o</bold> represents 10&#xA0;&#x3BC;m</p></caption><graphic xlink:href="401_2013_1096_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Distribution and morphology of &#x3B1;-synuclein immunoreactive inclusions</title>
        <p>Immunohistochemical staining for &#x3B1;-synuclein demonstrated widespread neuronal and glial inclusions (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Amongst the areas most severely affected by neuronal &#x3B1;-synuclein pathology was the hippocampus (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>a&#x2013;d), in which the DF and CA1 contained many inclusions. Inclusions were sparse in the CA2 and CA3 subregions reflecting the paucity of residual neurons in these areas. The caudate and putamen contained a remarkable load of neuronal &#x3B1;-synuclein-positive inclusions affecting all regions of each nucleus to a similar extent (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>e, f). In the neocortex, there was a distinct pattern in which the superficial and deep cortical laminae were most severely affected (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>g, h). NCIs had variable morphology; many were clearly defined globular inclusions resembling LBs (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>i), while others were annular or crescent shaped situated around the nucleus (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>j), less frequently they resembled neurofibrillary tangles (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>k). Small numbers of neurons showed a diffuse finely granular pattern of &#x3B1;-synuclein immunoreactivity (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>l). In most areas, neuronal inclusions were accompanied by threads of varying width, up to 10&#xA0;&#x3BC;m, representing &#x3B1;-synuclein accumulation in cell processes. In cross section, these appeared as dots and round&#x2013;oval structures. The argyrophilic nature of fibrillar &#x3B1;-synuclein inclusions was demonstrated using Gallyas silver impregnation (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>m&#x2013;o).</p>
      </sec>
      <sec id="Sec12">
        <title>Glial inclusions</title>
        <p>A significant numbers of glial, &#x3B1;-synuclein-positive inclusions were observed, many of which resembled the GCIs of MSA (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>a&#x2013;d) and thus are hereafter referred to as GCI-like, while others had appearances similar to coiled bodies (CBs) as previously described in PD [<xref ref-type="bibr" rid="CR81">81</xref>]. The distribution of GCI-like pathology also resembled MSA as they were most frequent in the pontine base, cerebellar white matter and in the white matter underlying the motor cortex (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). They were also immunoreactive for recognised GCI markers including &#x3B1;B-crystallin [<xref ref-type="bibr" rid="CR63">63</xref>]. Double immunofluorescence of &#x3B1;-synuclein with the oligodendroglial marker olig-2 confirmed that GCI-like inclusions were in oligodendrocytes (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>a&#x2013;d).<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Glial inclusions. Representative double immunofluorescence images probed with &#x3B1;-synuclein (<italic>red</italic>) and the oligodendroglial marker, olig2 (<italic>green</italic>). Composite merged images show &#x3B1;-synuclein immunoreactive inclusions in oligodendrocytes resembling GCIs in the white matter of the frontal cortex (<bold>a</bold>, <bold>d</bold>), the pons (<bold>b</bold>) and the alveus of the hippocampus (<bold>c</bold>). Close proximity is observed between a subset of activated microglia, as detected by iba-1 (<italic>green</italic>) and &#x3B1;-synuclein (<italic>red</italic>) inclusion containing neurons, this occasionally involved encircling of &#x3B1;-synuclein-containing neurons by iba-1-positive processes (<bold>e</bold>&#x2013;<bold>g</bold>). A small proportion of these microglia contained &#x3B1;-synuclein immunoreactivity (<bold>g</bold>, <italic>inset</italic><italic>arrowheads</italic>). A high level of reactive astrogliosis was detected throughout all brain regions examined, without evidence of &#x3B1;-synuclein expression within astrocytes or their processes (<bold>h</bold>&#x2013;<bold>j</bold>). DAPI nuclear stain (<italic>blue</italic>). <italic>Scale bar</italic> in <bold>j</bold> represents 50&#xA0;&#x3BC;m (<bold>a</bold>&#x2013;<bold>j</bold>). <italic>Scale bar</italic> in <bold>g</bold><italic>inset</italic> represents 25&#xA0;&#x3BC;m</p></caption><graphic xlink:href="401_2013_1096_Fig6_HTML" id="MO6"/></fig></p>
        <p>The relationship between microglia and astrocytes with &#x3B1;-synuclein pathology was also investigated. A subset of microglia, detected using the microglial marker iba-1, was observed in close proximity to, in some cases with processes encircling, &#x3B1;-synuclein inclusion containing neurons (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>e&#x2013;g). A small number of microglia investigated in both the hippocampus and neocortex contained thread-like &#x3B1;-synuclein immunoreactivity (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>g inset, arrows). Marked reactive astrogliosis, detected by GFAP immunofluorescence, was observed, however, double immunofluorescence studies showed no &#x3B1;-synuclein immunoreactivity in astrocytic processes in any regions including the severely affected CA2, where there was a high density of &#x3B1;-synuclein-positive threads (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>h&#x2013;j).</p>
      </sec>
      <sec id="Sec13">
        <title>Tau expression within neuronal inclusions and co-localisation with &#x3B1;-synuclein</title>
        <p>Phosphorylated tau was identified using immunohistochemical staining for AT8, recognising Ser202 and Thr205 (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>a). This demonstrated granular pre-tangles, neurofibrillary tangles and neuropil threads in the hippocampal formation, most frequent in the CA1, CA4 and subiculum. They were also present in moderate numbers in the entorhinal and transentorhinal cortices and DF (shown in the DF, Online resource 2). There was no neocortical tau pathology and only rare neuropil threads were found in the midbrain and pontine tegmenta. Overall the tau pathology conformed largely to Braak and Braak stage II Alzheimer-type pathology, although involvement of the DF at this stage would not be expected [<xref ref-type="bibr" rid="CR6">6</xref>]. Further support for Alzheimer-type tau deposition was provided using the AT100 antibody, recognising tau phosphorylated at Thr212 and Ser214 with paired helical filament conformation, which labelled a proportion of neurofibrillary tangles and by isoform specific antibodies, which showed a mixture of 3- and 4-repeat tau isoforms (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>b&#x2013;d).<fig id="Fig7"><label>Fig.&#xA0;7</label><caption><p>Tau expression and co-localisation with &#x3B1;-synuclein. Representative images from CA1 probed using immunohistochemistry with phospho-tau antibodies: AT8 (<bold>a</bold>) and AT100 (<bold>b</bold>). Inclusions contained a mixture of 3-repeat (<bold>c</bold>) and 4-repeat (<bold>d</bold>) tau isoforms. Double immunofluorescence images of CA2 (<bold>e</bold>&#x2013;<bold>i</bold>) and DF (<bold>j</bold>&#x2013;<bold>l</bold>) probed for &#x3B1;-synuclein (<italic>green</italic>) and AT8 (<italic>red</italic>) show strong co-localisation in a subset of neurons. AT8 immunoreactivity is detected on the dendritic processes of DF granule cells which express &#x3B1;-synuclein in the stratum lacunosum-moleculare (<italic>SLM</italic>, <bold>m</bold>&#x2013;<bold>p</bold>). DAPI nuclear stain (blue). <italic>Scale bars</italic> represent 50&#xA0;&#x3BC;m (<bold>b</bold>&#x2013;<bold>d</bold> are at the same magnification as are <bold>e</bold>&#x2013;<bold>g</bold>, <bold>j</bold>&#x2013;<bold>o</bold>)</p></caption><graphic xlink:href="401_2013_1096_Fig7_HTML" id="MO7"/></fig></p>
        <p>Double immunofluorescence microscopy was used to investigate the relationship between &#x3B1;-synuclein and tau. This showed that, particularly in the CA1 and DF, &#x3B1;-synuclein and tau co-localised in a proportion of inclusions (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>e&#x2013;l). In addition, AT8 immunoreactivity was detected on the dendritic processes of DF neurons in the stratum lacunosum-moleculare (SLM), which also expressed &#x3B1;-synuclein (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>m&#x2013;p).</p>
      </sec>
      <sec id="Sec14">
        <title>&#x3B1;-Synuclein within inclusions is phosphorylated and inclusions are immunoreactive for ubiquitin and p62</title>
        <p>&#x3B1;-Synuclein in LBs is widely reported to be extensively phosphorylated [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Double immunofluorescence staining for total &#x3B1;-synuclein and &#x3B1;-synuclein phospho-Ser129 (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>a&#x2013;c) or phospho-Y125 (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>d&#x2013;f) showed almost complete overlap of immunoreactivity within inclusions, implying the near total phosphorylation of &#x3B1;-synuclein at both epitopes. Ubiquitin and p62 co-localised with the majority of neuronal &#x3B1;-synuclein-positive inclusions (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>g&#x2013;l) and also GCI-like inclusions (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>m&#x2013;o).<fig id="Fig8"><label>Fig.&#xA0;8</label><caption><p>&#x3B1;-Synuclein is phosphorylated and inclusions contain ubiquitin and p62. Representative images of the CA2 region of the hippocampus probed by double immunofluorescence with total &#x3B1;-synuclein (<italic>red</italic>) and &#x3B1;-synuclein phospho-S129 (<italic>green</italic>) (<bold>a</bold>&#x2013;<bold>c</bold>), or &#x3B1;-synuclein (<italic>green</italic>) and &#x3B1;-synuclein phospho-Y125 (<italic>red</italic>) (<bold>d</bold>&#x2013;<bold>f</bold>) show near complete co-localisation indicating that &#x3B1;-synuclein is phosphorylated at both epitopes. The majority of &#x3B1;-synuclein immunoreactivity (<italic>green</italic>) within neuronal inclusions co-localised with ubiquitin (<italic>red</italic>), shown in CA1 neurons (<bold>g</bold>&#x2013;<bold>i</bold>). Many &#x3B1;-synuclein-positive (<italic>green</italic>) neuronal inclusions also contained P62 (<italic>red</italic>) (<bold>j</bold>&#x2013;<bold>l</bold>) and a similar pattern was observed in GCI-like inclusions illustrated in the white matter underlying the entorhinal cortex (<italic>EC</italic>, <bold>m</bold>&#x2013;<bold>o</bold>). DAPI nuclear stain (<italic>blue</italic>). <italic>Scale bars</italic> represent 50&#xA0;&#x3BC;m (<bold>a</bold>&#x2013;<bold>l</bold> are at the same magnification as are <bold>m</bold>&#x2013;<bold>o</bold>)</p></caption><graphic xlink:href="401_2013_1096_Fig8_HTML" id="MO8"/></fig></p>
      </sec>
      <sec id="Sec15">
        <title>Additional pathological findings</title>
        <p>TDP-43 immunohistochemistry identified moderate numbers of NCIs in the caudate and putamen (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>k), while these were sparse in the amygdala, DF, CA4, CA1, subiculum, entorhinal cortex and transentorhinal cortex. A single neuronal nuclear TDP-43 immunoreactive inclusion was noted in the entorhinal cortex. A&#x3B2; deposition was not detected.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>We provide detailed clinical, genetic and neuropathological characterisation of an &#x3B1;-synucleinopathy in a patient carrying a G51D &#x3B1;-synuclein mutation, clinically diagnosed with juvenile parkinsonism. Neuropathological analysis revealed a combination of the characteristic profile of SN and LC neuronal loss together with neuronal &#x3B1;-synuclein immunoreactive inclusions consistent with PD as well as severe hippocampal, cortical and striatal &#x3B1;-synuclein pathology. An additional feature was the presence of GCI-like oligodendroglial inclusions with a distribution similar to that found in MSA. This case shows some similarity to reports of A53T mutation and multiplication of <italic>SNCA</italic> (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) and also to a Japanese kindred reported in an abstract as carrying a G51D <italic>SNCA</italic> mutation, but without detailed segregation data [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. However, features including dense accumulation of &#x3B1;-synuclein-positive inclusions in the striatum and very severe neocortical &#x3B1;-synuclein pathology affecting both superficial and deep cortical laminae distinguish this case from other reported cases with <italic>SNCA</italic> mutations.<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Neuropathology of &#x3B1;-synuclein mutation cases where &#x3B1;-synuclein immunohistochemistry data are available</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2">Mutation</th><th align="left" rowspan="2">Number of cases (<italic>n</italic>)</th><th align="left" colspan="4">Neuronal loss</th><th align="left" colspan="4">&#x3B1;-Synuclein pathology</th><th align="left" rowspan="2">Tau Braak and Braak stage</th><th align="left" rowspan="2">TDP-43 pathology</th></tr><tr><th align="left">SN</th><th align="left">LC</th><th align="left">CA1</th><th align="left">CA2/3</th><th align="left">Pattern</th><th align="left">Striatum</th><th align="left">Neocortical distribution</th><th align="left">Glial inclusions</th></tr></thead><tbody><tr><td align="left">Golbe et al. [<xref ref-type="bibr" rid="CR26">26</xref>] and Duda et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left">A53T</td><td align="left">2</td><td align="left">Severe</td><td align="left">Mild&#x2013;moderate</td><td align="left">Yes</td><td align="left">No</td><td align="left">PD-like</td><td align="left">Moderate grains and threads</td><td align="left">Deep laminae</td><td align="left">Not described</td><td align="left">I</td><td align="left">Not described</td></tr><tr><td align="left">Spira et al. [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">A53T</td><td align="left">2</td><td align="left">Severe</td><td align="left">Severe</td><td align="left">No</td><td align="left">Severe</td><td align="left">PD-like</td><td align="left">None</td><td align="left">Deep laminae</td><td align="left">None</td><td align="left">0</td><td align="left">Not described</td></tr><tr><td align="left">Markopoulou et al. [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">A53T</td><td align="left">2</td><td align="left">Severe</td><td align="left">Mild</td><td align="left">Severe (<italic>n</italic>&#xA0;=&#xA0;1)</td><td align="left">CA2 (<italic>n</italic>&#xA0;=&#xA0;1)</td><td align="left">PD-like</td><td align="left">Grains and threads (<italic>n</italic>&#xA0;=&#xA0;1)</td><td align="left">Deep laminae</td><td align="left">Small numbers GCIs</td><td align="left">IV (<italic>n</italic>&#xA0;=&#xA0;1), I (<italic>n</italic>&#xA0;=&#xA0;1)</td><td align="left">Limbic and cortical (<italic>n</italic>&#xA0;=&#xA0;1, with CA1 neuronal loss)</td></tr><tr><td align="left">Seidel et al. [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left">A30P</td><td align="left">1</td><td align="left">Severe</td><td align="left">Not described</td><td align="left">Not described</td><td align="left">Not described</td><td align="left">PD-like</td><td align="left">LBs</td><td align="left">Deep laminae</td><td align="left">Small numbers CB and astrocytes of PD type</td><td align="left">II</td><td align="left">Not described</td></tr><tr><td align="left">Zarranz et al. [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">E46&#xA0;K</td><td align="left">1</td><td align="left">Moderate&#x2013;severe</td><td align="left">Mild</td><td align="left">Not described</td><td align="left">Not described</td><td align="left">PD-like</td><td align="left">None</td><td align="left">Present, distribution not described</td><td align="left">Not described</td><td align="left">0</td><td align="left">Not described</td></tr><tr><td align="left">Obi et al. [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Duplication</td><td align="left">1</td><td align="left">Severe</td><td align="left">Severe</td><td align="left">None</td><td align="left">Moderate</td><td align="left">Features of PD and MSA</td><td align="left">None</td><td align="left">Present, distribution not described</td><td align="left">Small numbers GCIs and CB</td><td align="left">I</td><td align="left">Not described</td></tr><tr><td align="left">Ikeuchi et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">Duplication</td><td align="left">1</td><td align="left">Severe</td><td align="left">Not described</td><td align="left">None</td><td align="left">Severe</td><td align="left">PD-like</td><td align="left">Not described</td><td align="left">Present, distribution not described</td><td align="left">Few, type not specified</td><td align="left">III</td><td align="left">Not described</td></tr><tr><td align="left">Gwinn-Hardy et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">Triplication</td><td align="left">1</td><td align="left">Severe</td><td align="left">Severe</td><td align="left">None</td><td align="left">Severe</td><td align="left">Features of PD and MSA</td><td align="left">LBs and neurites</td><td align="left">Predominantly deep laminae</td><td align="left">Small numbers GCIs and CB</td><td align="left">0</td><td align="left">Not described</td></tr><tr><td align="left">Farrer et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left">Triplication</td><td align="left">1</td><td align="left">Severe</td><td align="left">Severe</td><td align="left">None</td><td align="left">Severe</td><td align="left">PD-like<sup>a</sup></td><td align="left">Not described</td><td align="left">Present, distribution not described</td><td align="left">Not described</td><td align="left">Not described</td><td align="left">Not described</td></tr><tr><td align="left">This report</td><td align="left">G51D</td><td align="left">1</td><td align="left">Severe</td><td align="left">Severe</td><td align="left">Mild</td><td align="left">Severe</td><td align="left">Features of PD and MSA</td><td align="left">Frequent neuronal inclusions and threads</td><td align="left">Superficial and deep laminae</td><td align="left">GCIs and CB</td><td align="left">II</td><td align="left">Limbic</td></tr></tbody></table><table-wrap-foot><p><italic>SN</italic> substantia nigra, <italic>LC</italic> locus coeruleus, <italic>N/A</italic> not available, <italic>PD</italic> Parkinson&#x2019;s disease, <italic>CB</italic> coiled bodies</p><p><sup>a</sup>Detailed description of &#x3B1;-synuclein pathology not provided</p></table-wrap-foot></table-wrap></p>
      <p>In comparison with other reported mutations in the <italic>SNCA</italic> gene, the age of onset in this family, clinical features and progression are most similar to the <italic>SNCA</italic> triplication [<xref ref-type="bibr" rid="CR16">16</xref>] and A53T mutations, which are typically associated with young-onset PD frequently associated with cognitive impairment and hallucinations. This is similar to the family where the proband presented early at 19&#xA0;years while his father and sister presented at age 39 and 40&#xA0;years, respectively.</p>
      <p>In this family, an <italic>SNCA</italic> G&#xA0;&gt;&#xA0;A heterozygous mutation at codon 51 causes a glycine to aspartic acid amino acid change (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a), which segregates with the disease (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b) and was not found in over 4,500 control individuals. The G51D mutation is located in the N-terminal domain of the protein, a region required for lipid affinity and membrane binding and may thus influence these functions (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. As the A53T and E46K mutations result in faster fibrillisation of &#x3B1;-synuclein [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR62">62</xref>], we postulate that the G51D mutation might have a similar effect.</p>
      <p>The neuropathological findings included some features of both PD and MSA. In common with PD and MSA, there was severe neuronal loss in the SN. Neuronal &#x3B1;-synuclein pathology had a distribution compatible with PD in that brainstem, limbic and cortical regions were affected. Unusual for PD, however, was the severe neuronal loss in the CA2/3 subregions of the hippocampus and the extensive accumulation of neuronal &#x3B1;-synuclein in the hippocampus, including the DF, and striatum [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Involvement of the DF by neuronal &#x3B1;-synuclein inclusions has been described previously in the case of DLB with additional MSA-type pathology and in some cases of MSA [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. The severe neuronal loss observed in CA2/3 of this case bears similarity to that described in association with A53T <italic>SNCA</italic> mutation [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR77">77</xref>] and in cases of multiplication of <italic>SNCA</italic>, though this pattern of loss was suggested to be a unique feature of the latter [<xref ref-type="bibr" rid="CR21">21</xref>] (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). As frequently observed in PD and DLB, and also reported in conjunction with A53T <italic>SNCA</italic> mutation, &#x3B1;-synuclein-positive threads were frequent in CA2/3 [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The severe neuronal loss we observed is likely to be associated with the susceptibility of these hippocampal subregions to &#x3B1;-synuclein accumulation.</p>
      <p>Oligodendroglial pathology in the form of GCI-like inclusions in regions such as the posterior frontal white matter, pontine base and cerebellar white matter was also notable and prompts comparison with MSA. In common with GCIs in MSA, these inclusions were immunoreactive for &#x3B1;B-crystallin [<xref ref-type="bibr" rid="CR63">63</xref>]. Oligodendroglial pathology with similar morphological appearances has been described in cases with <italic>SNCA</italic> multiplication or A53T mutation (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) and, interestingly, was also reported in a sporadic DLB case [<xref ref-type="bibr" rid="CR74">74</xref>]. Neuronal and glial &#x3B1;-synuclein pathology in the striatum is also a common feature of MSA and we noted very frequent striatal neuronal &#x3B1;-synuclein immunoreactive inclusions coupled with severe gliosis. However, in notable contrast to MSA, in which the putamen has a gradient of pathology most severely affecting the posterior and dorsal aspects of this nucleus with less severe involvement of the caudate, there was a uniform distribution of pathology in all regions of both nuclei in this case [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. This pattern of striatal pathology appears to be unique to our case as it has not been described in the context of other <italic>SNCA</italic> mutations (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).</p>
      <p>Hippocampal sclerosis with severe neuronal loss affecting CA1 and the subiculum is a feature of many neurodegenerative diseases and is often associated with TDP-43 immunoreactive inclusions in residual neurons in these regions and elsewhere [<xref ref-type="bibr" rid="CR64">64</xref>]. TDP-43 pathology is reported to be frequent in DLB cases, but is considerably rarer in MSA and in PD [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. While we observed sparse TDP-43-positive inclusions in these areas, the overall pattern of neuronal loss, being most severe in CA2/3, did not resemble typical hippocampal sclerosis. Of particular note was the abundance of TDP-43 immunoreactive NCIs in the caudate and putamen, regions also vulnerable to TDP-43 pathology in FTLD-TDP [<xref ref-type="bibr" rid="CR9">9</xref>]. We did not observe TDP-43-positive inclusions in neocortex or brainstem motor nuclei. A further neuropathological feature, which may be distinctive in the G51D &#x3B1;-synuclein mutation, is the distribution of neocortical &#x3B1;-synuclein pathology. In PD, MSA and other <italic>SNCA</italic> mutations, &#x3B1;-synuclein pathology is predominantly found in the deep cortical laminae (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR77">77</xref>] compared with our observation of severe involvement of both the superficial and deep cortical layers.</p>
      <p>We further investigated the nature of intracellular inclusions and Gallyas silver impregnation indicated the presence of fibrillar protein. Phosphorylation of &#x3B1;-synuclein at Ser129 is a feature of LB pathology and may promote oligomerisation, while phosphorylation at Y125 may increase protein fibrillisation of &#x3B1;-synuclein [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Using immunofluorescence, we showed phosphorylation of &#x3B1;-synuclein at both Y125 and Ser129. Although the majority of neuronal and glial inclusions were immunoreactive for p62 and ubiquitin, a proportion remained unstained and these possibly represented an early phase of inclusion formation [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. A varying degree of tau pathology has been reported in cases of <italic>SNCA</italic> mutation or multiplication sometimes co-localising with &#x3B1;-synuclein in neuronal inclusions [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. We report tau pathology in the hippocampal formation and entorhinal cortex corresponding to Braak and Braak stage II, but with additional involvement of the DF. Phosphorylated tau co-localised with a subpopulation of neuronal &#x3B1;-synuclein inclusions, particularly in the CA1 and DF. A relationship between tau and both the levels and aggregation state of &#x3B1;-synuclein, such that greater numbers of tau-positive inclusions may increase &#x3B1;-synuclein pathology, is well described [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. More recently, it has been shown that &#x3B1;-synuclein oligomers can seed tau aggregation in vitro and this may explain the occurrence of tau in a proportion of &#x3B1;-synuclein-containing inclusions [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
      <p>The defining neuropathological hallmark of MSA is the presence of &#x3B1;-synuclein-containing GCIs coupled with neurodegeneration in the striatonigral and/or olivopontocerebellar regions [<xref ref-type="bibr" rid="CR79">79</xref>]. The mechanism of GCI formation is currently unknown and mature oligodendrocytes are not thought to express &#x3B1;-synuclein under normal circumstances [<xref ref-type="bibr" rid="CR76">76</xref>]. Evidence of GCI-like pathology in cases of <italic>SNCA</italic> multiplication [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], A53T mutation [<xref ref-type="bibr" rid="CR48">48</xref>] and in this case of G51D mutation, provide a strong link between these mutations and the pathological mechanisms of MSA. One of the earliest stages of MSA pathogenesis may involve the overexpression or aberrant localisation of &#x3B1;-synuclein in oligodendrocytes, where it becomes fibrillar [<xref ref-type="bibr" rid="CR69">69</xref>] and forms GCIs [<xref ref-type="bibr" rid="CR39">39</xref>]. Greater understanding of the effect of the G51D and A53T mutations and <italic>SNCA</italic> multiplication may shed further light on the pathological cascades, which result in GCI formation. The data presented indicate that G51D <italic>SNCA</italic> mutation results in a neuropathological profile, which shares some neuropathological features of both PD and MSA and, therefore understanding the consequences of this mutation, has the potential to provide greater insight into the role of &#x3B1;-synuclein mutation or dysfunction in the pathogenesis of PD and also MSA. Understanding the biology of this G51D <italic>SNCA</italic> mutation could help us to target pathways in PD, MSA and other synucleinopathies, which lead to neuronal and glial &#x3B1;-synuclein accumulation.</p>
    </sec>
    <sec sec-type="supplementary-material" id="AppESM1">
      <title>Electronic supplementary material</title>
      <sec id="SecESM1">
        <p>Online resource 2. Supplementary Fig.&#xA0;1 Phospho-tau immunoreactivity is detected in granule cells of the DF. Representative images from the DF of immunohistochemical staining for phospho-tau (AT8, a), &#x3B1;-synuclein (b) ubiquitin (c) and p62 (d) demonstrating that tau is present in a minority of neuronal inclusions. Scale bar in d represents 50&#xA0;&#x3BC;m in a&#x2013;d.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="401_2013_1096_MOESM1_ESM.docx" mimetype="application" mime-subtype="msword"><caption><p>Supplementary material 1 (DOCX 16&#xA0;kb)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="401_2013_1096_MOESM2_ESM.tif" mimetype="image" mime-subtype="tiff"><caption><p>Supplementary material 2 (TIFF 1430&#xA0;kb)</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>A&#x3B2;</term>
            <def>
              <p>Amyloid beta</p>
            </def>
          </def-item>
          <def-item>
            <term>ALS</term>
            <def>
              <p>Amyotrophic lateral sclerosis</p>
            </def>
          </def-item>
          <def-item>
            <term>CA</term>
            <def>
              <p>Cornu ammonis</p>
            </def>
          </def-item>
          <def-item>
            <term>CB</term>
            <def>
              <p>Coiled bodies</p>
            </def>
          </def-item>
          <def-item>
            <term>Cg</term>
            <def>
              <p>Cingulate gyrus</p>
            </def>
          </def-item>
          <def-item>
            <term>CN</term>
            <def>
              <p>Caudate nucleus</p>
            </def>
          </def-item>
          <def-item>
            <term>DF</term>
            <def>
              <p>Dentate fascia</p>
            </def>
          </def-item>
          <def-item>
            <term>DLB</term>
            <def>
              <p>Dementia with Lewy bodies</p>
            </def>
          </def-item>
          <def-item>
            <term>DMV</term>
            <def>
              <p>Dorsal motor nucleus of the vagus</p>
            </def>
          </def-item>
          <def-item>
            <term>FTLD</term>
            <def>
              <p>Frontotemporal lobar degeneration</p>
            </def>
          </def-item>
          <def-item>
            <term>GCI</term>
            <def>
              <p>Glial cytoplasmic inclusions</p>
            </def>
          </def-item>
          <def-item>
            <term>LB</term>
            <def>
              <p>Lewy bodies</p>
            </def>
          </def-item>
          <def-item>
            <term>LN</term>
            <def>
              <p>Lewy neurites</p>
            </def>
          </def-item>
          <def-item>
            <term>MSA</term>
            <def>
              <p>Multiple system atrophy</p>
            </def>
          </def-item>
          <def-item>
            <term>NAC</term>
            <def>
              <p>Non-amyloid-&#x3B2;-component</p>
            </def>
          </def-item>
          <def-item>
            <term>NCI</term>
            <def>
              <p>Neuronal cytoplasmic inclusions</p>
            </def>
          </def-item>
          <def-item>
            <term>NNI</term>
            <def>
              <p>Neuronal nuclear inclusions</p>
            </def>
          </def-item>
          <def-item>
            <term>PBs</term>
            <def>
              <p>Pale bodies</p>
            </def>
          </def-item>
          <def-item>
            <term>PNs</term>
            <def>
              <p>Pale neurites</p>
            </def>
          </def-item>
          <def-item>
            <term>PD</term>
            <def>
              <p>Parkinson&#x2019;s disease</p>
            </def>
          </def-item>
          <def-item>
            <term>Pt</term>
            <def>
              <p>Putamen</p>
            </def>
          </def-item>
          <def-item>
            <term>SLM</term>
            <def>
              <p>Stratum lacunosum-moleculare</p>
            </def>
          </def-item>
          <def-item>
            <term>SN</term>
            <def>
              <p>Substantia nigra</p>
            </def>
          </def-item>
          <def-item>
            <term>TAR-DNA-binding protein-43</term>
            <def>
              <p>TDP-43</p>
            </def>
          </def-item>
          <def-item>
            <term>WT</term>
            <def>
              <p>Wild type</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>H. Houlden, J. L. Holton are senior authors.</p>
      </fn>
    </fn-group>
    <ack>
      <p>JH, AL and TR are supported by Parkinson&#x2019;s UK, the Multiple System Atrophy Trust, Alzheimer&#x2019;s Research UK and the Progressive Supranuclear Palsy (Europe) Association. JH is supported by the Reta Lila Weston Institute for Neurological Studies. AK is supported by the Multiple System Atrophy Trust. YA is supported by the Government of Kuwait. HH is supported by the MRC, the DMRF and the Parkinson&#x2019;s disease foundation. The research was, in part, funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Dementia based at&#xA0;University College London Hospitals (UCLH), University College London (UCL). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This work was supported in part by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson&#x2019;s Disease Consortium (UKPDC) whose members are from&#xA0;the UCL Institute of Neurology, the University of Sheffield and the MRC&#xA0;Protein Phosphorylation Unit at the University of Dundee.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Asi</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Sailer</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The neuropathology, pathophysiology and genetics of multiple system atrophy</article-title>
          <source>Neuropathol Appl Neurobiol</source>
          <year>2012</year>
          <volume>38</volume>
          <fpage>4</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2990.2011.01234.x</pub-id>
          <pub-id pub-id-type="pmid">22074330</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Chalabi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Durr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>NW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy</article-title>
          <source>PLoS One</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>e7114</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0007114</pub-id>
          <pub-id pub-id-type="pmid">19771175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amador-Ortiz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>W-L</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease</article-title>
          <source>Ann Neurol</source>
          <year>2007</year>
          <volume>61</volume>
          <fpage>435</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.21154</pub-id>
          <pub-id pub-id-type="pmid">17469117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cairns</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Lantos</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Multiple system atrophy (MSA): topographic distribution of the alpha-synuclein-associated pathological changes</article-title>
          <source>Parkinsonism Relat Disord</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>356</fpage>
          <lpage>362</lpage>
          <pub-id pub-id-type="doi">10.1016/j.parkreldis.2006.02.005</pub-id>
          <pub-id pub-id-type="pmid">16723266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Athanassiadou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Voutsinas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>L</surname>
              <given-names>Psiouri</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein</article-title>
          <source>Am J Hum Genet</source>
          <year>1999</year>
          <volume>65</volume>
          <fpage>555</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="doi">10.1086/302486</pub-id>
          <pub-id pub-id-type="pmid">10417297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes</article-title>
          <source>Neurobiol Aging</source>
          <year>1995</year>
          <volume>16</volume>
          <fpage>271</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1016/0197-4580(95)00021-6</pub-id>
          <pub-id pub-id-type="pmid">7566337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Pathoanatomy of Parkinson&#x2019;s disease</article-title>
          <source>J Neurol</source>
          <year>2000</year>
          <volume>247</volume>
          <fpage>II3</fpage>
          <lpage>II10</lpage>
          <pub-id pub-id-type="doi">10.1007/PL00007758</pub-id>
          <pub-id pub-id-type="pmid">10991663</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tredici</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>R&#xFC;b</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>de Vos</surname>
              <given-names>RAI</given-names>
            </name>
            <name>
              <surname>Jansen Steur</surname>
              <given-names>ENH</given-names>
            </name>
            <name>
              <surname>Braak</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Staging of brain pathology related to sporadic Parkinson&#x2019;s disease</article-title>
          <source>Neurobiol Aging</source>
          <year>2003</year>
          <volume>24</volume>
          <fpage>197</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="doi">10.1016/S0197-4580(02)00065-9</pub-id>
          <pub-id pub-id-type="pmid">12498954</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandmeir</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Geser</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease</article-title>
          <source>Acta Neuropathol</source>
          <year>2008</year>
          <volume>115</volume>
          <fpage>123</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-007-0315-5</pub-id>
          <pub-id pub-id-type="pmid">18004574</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chartier-Harlin</surname>
              <given-names>M-C</given-names>
            </name>
            <name>
              <surname>Kachergus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Roumier</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>&#x3B1;-Synuclein locus duplication as a cause of familial Parkinson&#x2019;s disease</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>364</volume>
          <fpage>1167</fpage>
          <lpage>1169</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17103-1</pub-id>
          <pub-id pub-id-type="pmid">15451224</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Periquet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tyrosine and serine phosphorylation of &#x3B1;-synuclein have opposing effects on neurotoxicity and soluble oligomer formation</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>3257</fpage>
          <lpage>3265</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI35314</pub-id>
          <pub-id pub-id-type="pmid">19855133</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>H-I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease</article-title>
          <source>Neurogenetics</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>263</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1007/s10048-008-0138-0</pub-id>
          <pub-id pub-id-type="pmid">18704525</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zibaee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jakes</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation E46K increases phospholipid binding and assembly into filaments of human &#x3B1;-synuclein</article-title>
          <source>FEBS Lett</source>
          <year>2004</year>
          <volume>576</volume>
          <fpage>363</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="doi">10.1016/j.febslet.2004.09.038</pub-id>
          <pub-id pub-id-type="pmid">15498564</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clinton</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Blurton-Jones</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Myczek</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>JQ</given-names>
            </name>
            <name>
              <surname>LaFerla</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>Synergistic interactions between A&#x3B2;, tau, and &#x3B1;-synuclein: acceleration of neuropathology and cognitive decline</article-title>
          <source>J Neurosci</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>7281</fpage>
          <lpage>7289</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0490-10.2010</pub-id>
          <pub-id pub-id-type="pmid">20505094</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Compta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Parkkinen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>O&#x2019;Sullivan</surname>
              <given-names>SS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lewy- and Alzheimer-type pathologies in Parkinson&#x2019;s disease dementia: which is more important?</article-title>
          <source>Brain</source>
          <year>2011</year>
          <volume>134</volume>
          <fpage>1493</fpage>
          <lpage>1505</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awr031</pub-id>
          <pub-id pub-id-type="pmid">21596773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devine</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gwinn</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Singleton</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Parkinson&#x2019;s disease and &#x3B1;-synuclein expression</article-title>
          <source>Mov Disord</source>
          <year>2011</year>
          <volume>26</volume>
          <fpage>2160</fpage>
          <lpage>2168</lpage>
          <pub-id pub-id-type="doi">10.1002/mds.23948</pub-id>
          <pub-id pub-id-type="pmid">21887711</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>M-L</given-names>
            </name>
            <name>
              <surname>Yen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease</article-title>
          <source>Acta Neuropathol</source>
          <year>1994</year>
          <volume>87</volume>
          <fpage>269</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00296742</pub-id>
          <pub-id pub-id-type="pmid">7912027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickson</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Ruan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer&#x2019;s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD</article-title>
          <source>Neurology</source>
          <year>1991</year>
          <volume>41</volume>
          <fpage>1402</fpage>
          <lpage>1409</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.41.9.1402</pub-id>
          <pub-id pub-id-type="pmid">1653914</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duda</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Giasson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mabon</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred</article-title>
          <source>Acta Neuropathol</source>
          <year>2002</year>
          <volume>104</volume>
          <fpage>7</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-002-0563-3</pub-id>
          <pub-id pub-id-type="pmid">12070658</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eliezer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kutluay</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bussell</surname>
              <given-names>R</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Browne</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Conformational properties of &#x3B1;-synuclein in its free and lipid-associated states</article-title>
          <source>J Mol Biol</source>
          <year>2001</year>
          <volume>307</volume>
          <fpage>1061</fpage>
          <lpage>1073</lpage>
          <pub-id pub-id-type="doi">10.1006/jmbi.2001.4538</pub-id>
          <pub-id pub-id-type="pmid">11286556</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farrer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kachergus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Forno</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of kindreds with parkinsonism and &#x3B1;-synuclein genomic multiplications</article-title>
          <source>Ann Neurol</source>
          <year>2004</year>
          <volume>55</volume>
          <fpage>174</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.10846</pub-id>
          <pub-id pub-id-type="pmid">14755720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kachergus</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>68</volume>
          <fpage>916</fpage>
          <lpage>922</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000254458.17630.c5</pub-id>
          <pub-id pub-id-type="pmid">17251522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujiwara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dohmae</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>alpha-Synuclein is phosphorylated in synucleinopathy lesions</article-title>
          <source>Nat Cell Biol</source>
          <year>2002</year>
          <volume>4</volume>
          <fpage>160</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="doi">10.1038/ncb841</pub-id>
          <pub-id pub-id-type="pmid">11813001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geser</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Malunda</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hurtig</surname>
              <given-names>HI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TDP-43 pathology occurs infrequently in multiple system atrophy</article-title>
          <source>Neuropathol Appl Neurobiol</source>
          <year>2011</year>
          <volume>37</volume>
          <fpage>358</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2990.2010.01136.x</pub-id>
          <pub-id pub-id-type="pmid">20942898</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giasson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Interactions of amyloidogenic proteins</article-title>
          <source>Neuromolecular Med</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>49</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1385/NMM:4:1-2:49</pub-id>
          <pub-id pub-id-type="pmid">14528052</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golbe</surname>
              <given-names>LI</given-names>
            </name>
            <name>
              <surname>Di Iorio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bonavita</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Duvoisin</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>A large kindred with autosomal dominant Parkinson&#x2019;s disease</article-title>
          <source>Ann Neurol</source>
          <year>1990</year>
          <volume>27</volume>
          <fpage>276</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.410270309</pub-id>
          <pub-id pub-id-type="pmid">2158268</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gwinn-Hardy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p</article-title>
          <source>Acta Neuropathol</source>
          <year>2000</year>
          <volume>99</volume>
          <fpage>663</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="doi">10.1007/s004010051177</pub-id>
          <pub-id pub-id-type="pmid">10867800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halliday</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Holton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neuropathology underlying clinical variability in patients with synucleinopathies</article-title>
          <source>Acta Neuropathol</source>
          <year>2011</year>
          <volume>122</volume>
          <fpage>187</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-011-0852-9</pub-id>
          <pub-id pub-id-type="pmid">21720849</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hejjaoui</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Butterfield</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fauvet</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: &#x3B1;-synuclein phosphorylation at tyrosine 125</article-title>
          <source>J Am Chem Soc</source>
          <year>2012</year>
          <volume>134</volume>
          <fpage>5196</fpage>
          <lpage>5210</lpage>
          <pub-id pub-id-type="doi">10.1021/ja210866j</pub-id>
          <pub-id pub-id-type="pmid">22339654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Iseki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concurrence of TDP-43, tau and &#x3B1;-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies</article-title>
          <source>Brain Res</source>
          <year>2007</year>
          <volume>1184</volume>
          <fpage>284</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.1016/j.brainres.2007.09.048</pub-id>
          <pub-id pub-id-type="pmid">17963732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ib&#xE1;&#xF1;ez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>D&#xE9;barges</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Causal relation between &#x3B1;-synuclein locus duplication as a cause of familial Parkinson&#x2019;s disease</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>364</volume>
          <fpage>1169</fpage>
          <lpage>1171</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(04)17104-3</pub-id>
          <pub-id pub-id-type="pmid">15451225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ikeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kakita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shiga</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia</article-title>
          <source>Arch Neurol</source>
          <year>2008</year>
          <volume>65</volume>
          <fpage>514</fpage>
          <lpage>519</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.65.4.514</pub-id>
          <pub-id pub-id-type="pmid">18413475</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yagishita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ryo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Amano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsushita</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems</article-title>
          <source>Acta Neuropathol</source>
          <year>1997</year>
          <volume>93</volume>
          <fpage>585</fpage>
          <lpage>591</lpage>
          <pub-id pub-id-type="doi">10.1007/s004010050655</pub-id>
          <pub-id pub-id-type="pmid">9194897</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Irizarry</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Growdon</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gomez-Isla</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson&#x2019;s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity</article-title>
          <source>J Neuropathol Exp Neurol</source>
          <year>1998</year>
          <volume>57</volume>
          <fpage>334</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="doi">10.1097/00005072-199804000-00005</pub-id>
          <pub-id pub-id-type="pmid">9600226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iseki</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson&#x2019;s disease or Alzheimer&#x2019;s disease</article-title>
          <source>Neuropathology</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>72</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1440-1789.2003.00530.x</pub-id>
          <pub-id pub-id-type="pmid">15068176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jellinger</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Neuropathology of sporadic Parkinson&#x2019;s disease: evaluation and changes of concepts</article-title>
          <source>Mov Disord</source>
          <year>2012</year>
          <volume>27</volume>
          <fpage>8</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1002/mds.23795</pub-id>
          <pub-id pub-id-type="pmid">22081500</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>McLaurin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>St. George-Hyslop</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>&#x3B1;-Synuclein membrane interactions and lipid specificity</article-title>
          <source>J Biol Chem</source>
          <year>2000</year>
          <volume>275</volume>
          <fpage>34328</fpage>
          <lpage>34334</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M004345200</pub-id>
          <pub-id pub-id-type="pmid">10915790</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joelving</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Billeskov</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pakkenberg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Hippocampal neuron and glial cell numbers in Parkinson&#x2019;s disease&#x2014;a stereological study</article-title>
          <source>Hippocampus</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>826</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="doi">10.1002/hipo.20212</pub-id>
          <pub-id pub-id-type="pmid">16941622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kahle</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozmen</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes</article-title>
          <source>EMBO Rep</source>
          <year>2002</year>
          <volume>3</volume>
          <fpage>583</fpage>
          <lpage>588</lpage>
          <pub-id pub-id-type="doi">10.1093/embo-reports/kvf109</pub-id>
          <pub-id pub-id-type="pmid">12034752</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanazawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Adachi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Orimo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mizusawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uchihara</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Pale neurites, premature &#x3B1;-synuclein aggregates with centripetal extension from axon collaterals</article-title>
          <source>Brain Pathol</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>67</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1750-3639.2011.00509.x</pub-id>
          <pub-id pub-id-type="pmid">21672073</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanazawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Uchihara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Orimo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mizusawa</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Three-layered structure shared between Lewy bodies and Lewy neurites&#x2014;three-dimensional reconstruction of triple-labeled sections</article-title>
          <source>Brain Pathol</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>415</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00140.x</pub-id>
          <pub-id pub-id-type="pmid">18394008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ki</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Stavrou</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Davanos</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Ala53Thr mutation in the &#x3B1;-synuclein gene in a Korean family with Parkinson disease</article-title>
          <source>Clin Genet</source>
          <year>2007</year>
          <volume>71</volume>
          <fpage>471</fpage>
          <lpage>473</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1399-0004.2007.00781.x</pub-id>
          <pub-id pub-id-type="pmid">17489854</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ala30Pro mutation in the gene encoding [alpha]-synuclein in Parkinson&#x2019;s disease</article-title>
          <source>Nat Genet</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>106</fpage>
          <lpage>108</lpage>
          <pub-id pub-id-type="doi">10.1038/ng0298-106</pub-id>
          <pub-id pub-id-type="pmid">9462735</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuusisto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Parkkinen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alafuzoff</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62</article-title>
          <source>J Neuropathol Exp Neurol</source>
          <year>2003</year>
          <volume>62</volume>
          <fpage>1241</fpage>
          <lpage>1253</lpage>
          <pub-id pub-id-type="pmid">14692700</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lasagna-Reeves</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Castillo-Carranza</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Guerrero-Mu&#xF1;oz</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Kayed</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Preparation and characterization of neurotoxic tau oligomers</article-title>
          <source>Biochemistry (Mosc)</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>10039</fpage>
          <lpage>10041</lpage>
          <pub-id pub-id-type="doi">10.1021/bi1016233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>VMY</given-names>
            </name>
            <name>
              <surname>Giasson</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Trojanowski</surname>
              <given-names>JQ</given-names>
            </name>
          </person-group>
          <article-title>More than just two peas in a pod: common amyloidogenic properties of tau and &#x3B1;-synuclein in neurodegenerative diseases</article-title>
          <source>Trends Neurosci</source>
          <year>2004</year>
          <volume>27</volume>
          <fpage>129</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tins.2004.01.007</pub-id>
          <pub-id pub-id-type="pmid">15036877</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lemkau</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Comellas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kloepper</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Woods</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rienstra</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Mutant protein A30P &#x3B1;-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics</article-title>
          <source>J Biol Chem</source>
          <year>2012</year>
          <volume>287</volume>
          <fpage>11526</fpage>
          <lpage>11532</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.306902</pub-id>
          <pub-id pub-id-type="pmid">22334684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markopoulou</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McComb</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson&#x2019;s disease</article-title>
          <source>Acta Neuropathol</source>
          <year>2008</year>
          <volume>116</volume>
          <fpage>25</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-008-0372-4</pub-id>
          <pub-id pub-id-type="pmid">18389263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michell</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Raha-Chowdhury</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Raha</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>A case of late onset sporadic Parkinson&#x2019;s disease with an A53T mutation in &#x3B1;-synuclein</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <year>2005</year>
          <volume>76</volume>
          <fpage>596</fpage>
          <lpage>597</lpage>
          <pub-id pub-id-type="doi">10.1136/jnnp.2004.046425</pub-id>
          <pub-id pub-id-type="pmid">15774457</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mizutani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inose</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Familial parkinsonism and dementia with ballooned neurons, argyrophilic neuronal inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles, and Lewy bodies</article-title>
          <source>Acta Neuropathol</source>
          <year>1997</year>
          <volume>95</volume>
          <fpage>15</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.1007/s004010050761</pub-id>
          <pub-id pub-id-type="pmid">9452818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="other">Mizutani T, Mitsui J, Ozawa T et al (2009) Familial parkinsonism and dementia with ballooned neurons, argyrophilic neuronal inclusions, atypical neurofibrillary tangles, tau-negative astrocytic fibrillary tangles, and Lewy bodies&#x2014;further observations. In: Clinicopathological conference on dementia with Lewy bodies and Parkinson&#x2019;s disease dementia: symposium 5. News from neuropathology of DLB and PDD 08.03.2009&#x2013;10.03.2009</mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mori</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tanji</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kakita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wakabayashi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>&#x3B1;-Synuclein pathology in the neostriatum in Parkinson&#x2019;s disease</article-title>
          <source>Acta Neuropathol</source>
          <year>2008</year>
          <volume>115</volume>
          <fpage>453</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-007-0316-4</pub-id>
          <pub-id pub-id-type="pmid">18000672</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakashima-Yasuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uryu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases</article-title>
          <source>Acta Neuropathol</source>
          <year>2007</year>
          <volume>114</volume>
          <fpage>221</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-007-0261-2</pub-id>
          <pub-id pub-id-type="pmid">17653732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Negro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brunati</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Donella-Deana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Massimino</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Pinna</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Multiple phosphorylation of &#x3B1;-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation</article-title>
          <source>FASEB J</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>210</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">11744621</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishioka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical heterogeneity of &#x3B1;-synuclein gene duplication in Parkinson&#x2019;s disease</article-title>
          <source>Ann Neurol</source>
          <year>2006</year>
          <volume>59</volume>
          <fpage>298</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.20753</pub-id>
          <pub-id pub-id-type="pmid">16358335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nuytemans</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Meeus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Crosiers</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population</article-title>
          <source>Hum Mutat</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>1054</fpage>
          <lpage>1061</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.21007</pub-id>
          <pub-id pub-id-type="pmid">19405094</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishioka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>OA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clincopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia</article-title>
          <source>Neurology</source>
          <year>2008</year>
          <volume>70</volume>
          <fpage>238</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1212/01.wnl.0000299387.59159.db</pub-id>
          <pub-id pub-id-type="pmid">18195271</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Paviour</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>NP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations</article-title>
          <source>Brain</source>
          <year>2004</year>
          <volume>127</volume>
          <fpage>2657</fpage>
          <lpage>2671</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awh303</pub-id>
          <pub-id pub-id-type="pmid">15509623</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papadimitriou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Veletza</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hadjigeorgiou</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Patrikiou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Anastasopoulos</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Mutated &#x3B1;-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?</article-title>
          <source>Neurology</source>
          <year>1999</year>
          <volume>52</volume>
          <fpage>651</fpage>
          <pub-id pub-id-type="doi">10.1212/WNL.52.3.651</pub-id>
          <pub-id pub-id-type="pmid">10025809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papp</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Lantos</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)</article-title>
          <source>J Neurol Sci</source>
          <year>1989</year>
          <volume>94</volume>
          <fpage>79</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1016/0022-510X(89)90219-0</pub-id>
          <pub-id pub-id-type="pmid">2559165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polymeropoulos</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lavedan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leroy</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>276</volume>
          <fpage>2045</fpage>
          <lpage>2047</lpage>
          <pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id>
          <pub-id pub-id-type="pmid">9197268</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polymeropoulos</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Golbe</surname>
              <given-names>LI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mapping of a gene for Parkinson&#x2019;s disease to chromosome 4q21-q23</article-title>
          <source>Science</source>
          <year>1996</year>
          <volume>274</volume>
          <fpage>1197</fpage>
          <lpage>1199</lpage>
          <pub-id pub-id-type="doi">10.1126/science.274.5290.1197</pub-id>
          <pub-id pub-id-type="pmid">8895469</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pountney</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Treweek</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Chataway</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy</article-title>
          <source>Neurotox Res</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>77</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1007/BF03033778</pub-id>
          <pub-id pub-id-type="pmid">15639800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Probst</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tolnay</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hippocampal sclerosis dementia: a reappraisal</article-title>
          <source>Acta Neuropathol</source>
          <year>2007</year>
          <volume>114</volume>
          <fpage>335</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-007-0262-1</pub-id>
          <pub-id pub-id-type="pmid">17639426</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="other">Proukakis C, Dudzik CG, Breier T et al (2012) A novel alpha-synuclein missense mutation in Parkinson&#x2019;s disease. Neurology (in press)</mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Puschmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Vilari&#xF1;o-G&#xFC;ell</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Swedish family with de novo &#x3B1;-synuclein A53T mutation: evidence for early cortical dysfunction</article-title>
          <source>Parkinsonism Relat Disord</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>627</fpage>
          <lpage>632</lpage>
          <pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.06.007</pub-id>
          <pub-id pub-id-type="pmid">19632874</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quinn</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Critchley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Marsden</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Young onset Parkinson&#x2019;s disease</article-title>
          <source>Mov Disord</source>
          <year>1987</year>
          <volume>2</volume>
          <fpage>73</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1002/mds.870020201</pub-id>
          <pub-id pub-id-type="pmid">3504266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rhoades</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ramlall</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Eliezer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Quantification of &#x3B1;-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy</article-title>
          <source>Biophys J</source>
          <year>2006</year>
          <volume>90</volume>
          <fpage>4692</fpage>
          <lpage>4700</lpage>
          <pub-id pub-id-type="doi">10.1529/biophysj.105.079251</pub-id>
          <pub-id pub-id-type="pmid">16581836</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riedel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goldbaum</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Richter-Landsberg</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>&#x3B1;-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress</article-title>
          <source>J Mol Neurosci</source>
          <year>2009</year>
          <volume>39</volume>
          <fpage>226</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1007/s12031-009-9190-y</pub-id>
          <pub-id pub-id-type="pmid">19266322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Vilarino-Guell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wszolek</surname>
              <given-names>ZK</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Dickson</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Reply to: SNCA variants are associated with increased risk of multiple system atrophy</article-title>
          <source>Ann Neurol</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>414</fpage>
          <lpage>415</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.21786</pub-id>
          <pub-id pub-id-type="pmid">20373361</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scholz</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Houlden</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schulte</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SNCA variants are associated with increased risk for multiple system atrophy</article-title>
          <source>Ann Neurol</source>
          <year>2009</year>
          <volume>65</volume>
          <fpage>610</fpage>
          <lpage>614</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.21685</pub-id>
          <pub-id pub-id-type="pmid">19475667</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seidel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sch&#xF6;ls</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nuber</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>First appraisal of brain pathology owing to A30P mutant alpha-synuclein</article-title>
          <source>Ann Neurol</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>684</fpage>
          <lpage>689</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.22078</pub-id>
          <pub-id pub-id-type="pmid">20437567</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibuya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagatomo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iwabuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yagishita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Itoh</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Asymmetrical temporal lobe atrophy with massive neuronal inclusions in multiple system atrophy</article-title>
          <source>J Neurol Sci</source>
          <year>2000</year>
          <volume>179</volume>
          <fpage>50</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-510X(00)00364-6</pub-id>
          <pub-id pub-id-type="pmid">11054485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sikorska</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Papierz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Preusser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liberski</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Budka</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Synucleinopathy with features of both multiple system atrophy and dementia with Lewy bodies</article-title>
          <source>Neuropathol Appl Neurobiol</source>
          <year>2007</year>
          <volume>33</volume>
          <fpage>126</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">17239015</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singleton</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Farrer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>&#x3B1;-Synuclein locus triplication causes Parkinson&#x2019;s disease</article-title>
          <source>Science</source>
          <year>2003</year>
          <volume>302</volume>
          <fpage>841</fpage>
          <pub-id pub-id-type="doi">10.1126/science.1090278</pub-id>
          <pub-id pub-id-type="pmid">14593171</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solano</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Augood</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Penney</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Expression of &#x3B1;-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson&#x2019;s disease</article-title>
          <source>Ann Neurol</source>
          <year>2000</year>
          <volume>47</volume>
          <fpage>201</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1002/1531-8249(200002)47:2&lt;201::AID-ANA10&gt;3.0.CO;2-F</pub-id>
          <pub-id pub-id-type="pmid">10665491</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spira</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Sharpe</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Halliday</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cavanagh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr &#x3B1;-synuclein mutation</article-title>
          <source>Ann Neurol</source>
          <year>2001</year>
          <volume>49</volume>
          <fpage>313</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.67</pub-id>
          <pub-id pub-id-type="pmid">11261505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Komori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Oda</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Neuronal inclusions in the dentate fascia in patients with multiple system atrophy</article-title>
          <source>Neurosci Lett</source>
          <year>1997</year>
          <volume>227</volume>
          <fpage>157</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="doi">10.1016/S0304-3940(97)00336-4</pub-id>
          <pub-id pub-id-type="pmid">9185674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trojanowski</surname>
              <given-names>JQ</given-names>
            </name>
            <name>
              <surname>Revesz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy</article-title>
          <source>Neuropathol Appl Neurobiol</source>
          <year>2007</year>
          <volume>33</volume>
          <fpage>615</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2990.2007.00907.x</pub-id>
          <pub-id pub-id-type="pmid">17990994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ulmer</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Bax</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Nussbaum</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>Structure and dynamics of micelle-bound human &#x3B1;-synuclein</article-title>
          <source>J Biol Chem</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>9595</fpage>
          <lpage>9603</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M411805200</pub-id>
          <pub-id pub-id-type="pmid">15615727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wakabayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yoshimoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kudo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>NACP/&#x3B1;-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson&#x2019;s disease brains</article-title>
          <source>Acta Neuropathol</source>
          <year>2000</year>
          <volume>99</volume>
          <fpage>14</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1007/PL00007400</pub-id>
          <pub-id pub-id-type="pmid">10651022</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waxman</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Giasson</surname>
              <given-names>BI</given-names>
            </name>
          </person-group>
          <article-title>Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein</article-title>
          <source>J Neuropathol Exp Neurol</source>
          <year>2008</year>
          <volume>67</volume>
          <fpage>402</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="doi">10.1097/NEN.0b013e3186fc995</pub-id>
          <pub-id pub-id-type="pmid">18451726</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yun</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Jeon</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>SNCA variants and multiple system atrophy</article-title>
          <source>Ann Neurol</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>554</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.21889</pub-id>
          <pub-id pub-id-type="pmid">20437598</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zarranz</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Alegre</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>G&#xF3;mez-Esteban</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The new mutation, E46K, of &#x3B1;-synuclein causes Parkinson and Lewy body dementia</article-title>
          <source>Ann Neurol</source>
          <year>2004</year>
          <volume>55</volume>
          <fpage>164</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.10795</pub-id>
          <pub-id pub-id-type="pmid">14755719</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
